BBNX
Beta Bionics, Inc. Common StockBBNX
BBNX
About: Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
Employees: 294
–
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
81%
upside
Avg. target
$27
141%
upside
High target
$31
181%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
Stifel Mathew Blackman 35% 1-year accuracy 6 / 17 met price target | 126%upside $25 | Buy Initiated | 24 Feb 2025 |
Lake Street Brooks O'Neil 50% 1-year accuracy 8 / 16 met price target | 171%upside $30 | Buy Initiated | 24 Feb 2025 |
Piper Sandler Matt O'Brien 46% 1-year accuracy 23 / 50 met price target | 135%upside $26 | Overweight Initiated | 24 Feb 2025 |
Leerink Partners Mike Kratky 25% 1-year accuracy 1 / 4 met price target | 153%upside $28 | Outperform Initiated | 24 Feb 2025 |
Ladenburg Thalmann Jeff Cohen 25% 1-year accuracy 1 / 4 met price target | 181%upside $31 | Buy Initiated | 20 Feb 2025 |
Financial journalist opinion
Negative
Seeking Alpha
6 days ago
Beta Bionics: Slowing Down Or Being Conservative?
Beta Bionics' iLet product offers a simplified diabetes treatment, but shares have plunged 60% since the IPO due to a non-inspiring 2025 outlook, indicating potential lost market momentum. Despite strong initial growth and a significant IPO, the company's operating losses and competitive risks warrant a cautious investment stance. The 2025 sales guidance of $80-$85 million implies no sequential growth, raising concerns about market competitiveness and potential margin pressure.
Neutral
GlobeNewsWire
3 weeks ago
Beta Bionics to Host Investor Event on June 22, 2025
IRVINE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it will host an investor event on Sunday, June 22, 2025, in conjunction with the 85th Scientific Sessions of the American Diabetes Association (ADA) taking place June 20-23, 2025, in Chicago, IL. The event will begin at 7:00 am Central Time (8:00 am Eastern Time) and conclude at approximately 8:30 am Central Time (9:30 am Eastern Time).
Neutral
GlobeNewsWire
1 month ago
Beta Bionics Announces Board Appointment of Gerard Michel
IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (Nasdaq: DCTH), a commercial-stage interventional oncology company.
Neutral
GlobeNewsWire
1 month ago
Beta Bionics Announces Fourth Quarter and Full Year 2024 Financial Results and Introduces Annual Guidance for Full Year 2025
IRVINE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended December 31, 2024 and introduced its annual guidance for the year ending December 31, 2025.
Neutral
GlobeNewsWire
2 months ago
Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2024 performance.
Positive
24/7 Wall Street
2 months ago
Insider Buying Surges in February, Especially in These 6 Stocks
In January, the number of notable insider purchases was somewhat muted.
Positive
Seeking Alpha
2 months ago
Beta Bionics: A Sugar Rush For This IPO
Beta Bionics' IPO was highly successful, trading 40% above the offer price due to strong growth prospects and relatively cheap sales multiples. The company's iLet product offers a new, simplified treatment for Type 1 diabetes, with plans to expand to Type 2, doubling the market potential. Despite impressive revenue growth, Beta Bionics faces substantial operating losses, but it has a solid cash position to fund these losses for years.
Positive
Seeking Alpha
2 months ago
U.S. IPO Weekly Recap: Active January Closes Out With Several Sizable IPOs
Five IPOs listed this week, all of which raised over $100 million; one direct listing and three SPACs also debuted. Four microcaps submitted initial filings this week - Vistek, Awaysis Capital, QMSK Technology, and TV Channels Network. Two IPOs are currently scheduled for the week ahead, and a few more sizable names are eligible to launch.
Neutral
GlobeNewsWire
2 months ago
Beta Bionics Announces Closing of $234.6 Million Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
IRVINE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the closing of its upsized initial public offering of 13,800,000 shares of common stock, including the full exercise of the underwriters' option to purchase 1,800,000 additional shares, consisting of 475,000 additional shares from Beta Bionics and 1,325,000 shares from the selling stockholders named in the prospectus, at a price to the public of $17.00 per share. The gross proceeds to Beta Bionics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Beta Bionics, were approximately $212.1 million. Beta Bionics did not receive any proceeds from any sale of shares by the selling stockholders. The shares began trading on the Nasdaq Global Market on January 30, 2025 under the ticker symbol “BBNX.”
Neutral
GlobeNewsWire
2 months ago
Beta Bionics Announces Pricing of Upsized $204 Million Initial Public Offering
IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, today announced the pricing of its upsized initial public offering of 12,000,000 shares of common stock at a price to the public of $17.00 per share. The gross proceeds to Beta Bionics from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Beta Bionics, are expected to be $204.0 million. In addition, the underwriters have a 30-day option to purchase up to an additional 1,800,000 shares of common stock at the public offering price, less underwriting discounts and commissions, consisting of 475,000 shares from Beta Bionics and 1,325,000 shares from the selling stockholders named in the prospectus. Beta Bionics will not receive any proceeds from any sale of shares by the selling stockholders.
Charts implemented using Lightweight Charts™